Skip to main
MBX

MBX Stock Forecast & Price Target

MBX Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 50%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 10%

Bulls say

MBX Biosciences is a promising clinical stage biopharmaceutical company with a strong focus on developing innovative, precision peptide therapies for endocrine and metabolic disorders. The company's proprietary PEP platform allows for optimized pharmaceutical properties and extended drug action and exposure, leading to less frequent dosing. Early Phase 1 data for MBX 4291, a GLP-1/GIP co-agonist for obesity, showed promising results with potent weight loss and good GI tolerability, supporting its potential for once-monthly dosing. Upcoming catalysts for the company include the nomination of an amycretin prodrug candidate and the initiation of a Phase 3 trial for canvuparatide in hypoparathyroidism, adding to its diversified pipeline and growth potential. With a differentiated profile and strong potential, we maintain a positive outlook on MBX Biosciences Inc.

Bears say

MBX Biosciences is a clinical stage biopharmaceutical company with a promising pipeline of product candidates focused on endocrine and metabolic disorders. However, the recent weight loss data from its lead candidate, MBX 4291, showed a modest average weight reduction of 7% after just eight weeks, which may raise concerns about the effectiveness and market potential of its PEP platform. In addition, the company's lack of approved products and ongoing financial losses pose potential risks to its valuation and future commercial success, especially in a highly competitive obesity market.

MBX has been analyzed by 10 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 10% predict a Strong Sell.

This aggregate rating is based on analysts' research of MBX Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MBX Biosciences Inc (MBX) Forecast

Analysts have given MBX a Buy based on their latest research and market trends.

According to 10 analysts, MBX has a Buy consensus rating as of May 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $61.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $61.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MBX Biosciences Inc (MBX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.